(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Exhibit No. | Description | |||||||
99.1 | — | |||||||
EX-104 | — | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
Lexicon Pharmaceuticals, Inc. | ||||||||
Date: May 6, 2021 | By: | /s/ Brian T. Crum | ||||||
Brian T. Crum | ||||||||
Vice President and General Counsel |
Lexicon Pharmaceuticals, Inc. | |||||||||||||||||
Selected Financial Data | |||||||||||||||||
Consolidated Statements of Operations Data | Three Months Ended March 31, | ||||||||||||||||
(In thousands, except per share data) | 2021 | 2020 | |||||||||||||||
(Unaudited) | |||||||||||||||||
Revenues: | |||||||||||||||||
Net product revenue | $ | — | $ | 7,877 | |||||||||||||
Collaborative agreements | — | 8 | |||||||||||||||
Royalties and other revenue | 27 | 114 | |||||||||||||||
Total revenues | 27 | 7,999 | |||||||||||||||
Operating expenses: | |||||||||||||||||
Cost of sales (including finite-lived intangible | |||||||||||||||||
asset amortization) | — | 568 | |||||||||||||||
Research and development, including stock-based compensation of $1,286 and $2,176 respectively | 12,609 | 55,181 | |||||||||||||||
Selling, general and administrative, including stock-based compensation of $1,565 and $2,256 respectively | 8,257 | 14,688 | |||||||||||||||
Total operating expenses | 20,866 | 70,437 | |||||||||||||||
Loss from operations | (20,839) | (62,438) | |||||||||||||||
Interest expense | (167) | (5,131) | |||||||||||||||
Interest and other income, net | 48 | 958 | |||||||||||||||
Net loss | $ | (20,958) | $ | (66,611) | |||||||||||||
Net loss per common share, basic and diluted | $ | (0.15) | $ | (0.63) | |||||||||||||
Shares used in computing net loss per common share, basic and diluted | 143,379 | 106,536 | |||||||||||||||
Consolidated Balance Sheet Data | As of March 31, 2021 | As of December 31, 2020 | |||||||||||||||
(In thousands) | (Unaudited) | ||||||||||||||||
Cash and investments | $ | 141,361 | $ | 152,275 | |||||||||||||
Property and equipment, net | 296 | 295 | |||||||||||||||
Goodwill | 44,543 | 44,543 | |||||||||||||||
Total assets | 193,260 | 203,788 | |||||||||||||||
Current and long-term debt | 11,660 | 11,646 | |||||||||||||||
Accumulated deficit | (1,420,976) | (1,400,018) | |||||||||||||||
Total stockholders' equity | 152,547 | 156,371 |
Cover |
May 06, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 06, 2021 |
Entity Registrant Name | Lexicon Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 000-30111 |
Entity Tax Identification Number | 76-0474169 |
Entity Address, Address Line One | 8800 Technology Forest Place |
Entity Address, City or Town | The Woodlands |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77381 |
City Area Code | 281 |
Local Phone Number | 863-3000 |
Title of 12(b) Security | Common Stock, par value $0.001 |
Trading Symbol | LXRX |
Security Exchange Name | NASDAQ |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001062822 |
Amendment Flag | false |
9ZK6JM$Y>;QYR\:!U)IJ(, SSP]#@.7RF!K])M1_T["GQ#7GWS&T MRMC]X$-H4YU9)LD?(CVZ9AL4^_W. %LG?K5#^+C'%W4%KFZ3,D#
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end
MOHE1UP"E8^CL?:>)*!!^EVFN#Q1,<>6P[$@*V:8SD=Q
M$245AGJ0!KA:->F=D56_[88VEX['$3.VE/GXJ8]UVHR@1#\@4@7#F(YUSJ
M2W:<_.,$3!Y6-HZYIZ(R]=#)^#E,!!R,HDHV8XXKYNNO8YSJU;Q9+"):(4 3
M.LG",<9YA?%1Z$Q_5R[F*\7Y7YMY:^YWBZ8MY,O%^MIGM:KY>J7V2],N7M*R
MUD\"JYZWBH6U VOFP5XN]>21D@4M#R!QTJ?>[P=6[6"BO?RXX#\2:[RY7-N4
M2;G3(O=RQT/GI61FN@PS\\SC4 %W#^];YNJ3&*.&L',:TED83YAYJZ8. Z2I
M4)PB@HDD2$G3JPV-;6)RVMP'P@J7.P0I>K*!>68.G2E*T\_,D"0\L_%*